SynthesisBrain and behavior2025
Efficacy of Different Combination Therapies for Mania in Bipolar Disorder: A Systematic Review and Meta-Analysis.
Synthesis in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Different Combination Therapies for Mania in Bipolar Disorder: A Systematic Review and Meta-Analysis.Brain and behavior · 2025Pooled it
- Memory Impairments: Type, Causes, and Molecular Players-Memory Dysfunction Across Neurologic Insults.Cells · 2026Review
- Clinical characteristics and risk factors of antipsychotic-associated metabolic syndrome in bipolar disorder: a retrospective analysis.BMC psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the efficacy and safety of different combination therapies in the treatment of mania in bipolar disorder, and to provide evidence-based support for individualized clinical treatment.
methodsPubMed, Web of Science, Cochrane Library, CNKI, VIP, and Wanfang databases were systematically searched from inception to July 2025. Randomized controlled trials comparing ziprasidone or olanzapine combined with mood stabilizers (lithium carbonate or sodium valproate) for the treatment of manic episodes in bipolar disorder were included. Two reviewers independently performed literature screening, data extraction, and quality assessment. Meta-analysis was conducted using RevMan 5.4 software.
resultsA total of 10 RCTs involving 842 patients were included. Meta-analysis showed no significant difference between the two groups in overall clinical efficacy (OR = 1.18, 95% CI: 0.80-1.75, p = 0.41). Ziprasidone was superior to olanzapine in reducing YMRS scores (MD = -1.47, 95% CI: -1.97-0.96, p < 0.00001). The incidence of adverse reactions was significantly lower in the ziprasidone group compared to the olanzapine group (OR = 0.16, 95% CI: 0.08-0.31, p < 0.00001). Furthermore, ziprasidone was associated with significantly greater increases in BDNF and T
conclusionAlthough the efficacy of ziprasidone plus mood stabilizers is comparable to that of olanzapine plus mood stabilizers in the treatment of manic episodes of bipolar disorder, ziprasidone offers advantages in improving manic symptoms (YMRS scores), reducing adverse events, and enhancing neuroendocrine indicators. It may serve as a favorable alternative in clinical practice. Further high-quality, multicenter, large-sample studies are needed to confirm its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.